News from sanofi A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

17 Dec, 2019, 12:55 GMT Sanofi Wins Prestigious Drug Discovery Award for Innovative Rare Blood Clotting Disorder Treatment[1]

Sanofi's Cablivi® (caplacizumab), the first nanobody therapy for the treatment of acquired Thrombotic Thrombocytopenic Purpura (aTTP), has been...


08 May, 2019, 13:45 BST Sanofi Announces Licensing of Dupixent® ▼ (dupilumab) in the EU for the Treatment of Severe Asthma With Type 2 Inflammation[1]

FOR UK MEDIA ONLY The first biologic licensed in the EU for severe asthma with type 2 inflammation, as characterised by raised blood eosinophils...


06 Feb, 2019, 08:30 GMT Isatuximab Phase 3 Trial Meets Primary Endpoint of Prolonging Progression Free Survival in Patients With Relapsed/Refractory Multiple Myeloma

ICARIA (Isatuximab in Combination with pomalidomide And low-dose dexamethasone veRsus pomalidomide and low dose dexamethasone in patients with...


05 Jun, 2018, 07:00 BST New England Journal of Medicine Publishes Cemiplimab Trial Results in Advanced Cutaneous Squamous Cell Carcinoma[1]

Patients treated with cemiplimab experienced robust anti-tumour effects[1] Data also presented today at the 2018 ASCO Annual Meeting[2],[3]...


15 May, 2018, 07:00 BST It Affects Over 1.5 Million People in the UK. [1],[2] In a Survey, 80% Report that it Impacts their Mood, Mental Health and Well-Being. But What is Atopic Dermatitis?

Not intended for Irish media Atopic dermatitis is the most common type of eczema[3] New public awareness campaign Scratch Beneath the Surface...


21 Jul, 2017, 13:07 BST Sanofi Receives CHMP Positive Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis

FOR UK MEDIA ONLY First investigational targeted biologic in the European Union to receive positive CHMP opinion for atopic dermatitis Sanofi and its ...


27 Jun, 2017, 06:47 BST Sanofi Announces Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA) in the European Union

- Marketing authorisation for sarilumab offers a new treatment option for people in Ireland living with the debilitating effects of RA - Sanofi and...


27 Jun, 2017, 06:45 BST Sanofi Announces Licensing of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA) in the European Union

- Marketing authorisation for sarilumab offers a new treatment option for people in the UK living with the debilitating effects of RA - Sanofi and...


14 Mar, 2017, 21:29 GMT UK Patients Granted Early Access to Sanofi's Innovative Dermatology Treatment Dupilumab by MHRA

PRESS RELEASE - CORRECTION Positive scientific opinion under Early Access to Medicines Scheme (EAMS) recognises burden of severe atopic dermatitis...


08 Feb, 2017, 08:02 GMT Sanofi CEO Interview - FY 2016 Results (video)

Sanofi, a global and diversified healthcare leader, reports results for 2016. Olivier Brandicourt, Chief Executive Officer of Sanofi, comments on the ...


01 Feb, 2017, 07:00 GMT Sanofi Appoints Hugo Fry as General Manager UK

- Dr Hubert Bland appointed as UK Medical Chair and Medical Head of Diabetes and Cardiovascular for UK & Ireland - Sanofi today announces the...


12 Dec, 2016, 17:29 GMT Scottish Medicines Consortium Approves Sanofi Prostate Cancer Drug

Jevtana® (cabazitaxel) for Men With Metastatic Hormone-refractory Prostate Cancer Accepted for Routine use in NHS Scotland Sanofi Genzyme, the...


18 Nov, 2016, 12:19 GMT Global Survey into Perceptions of Men’s Health Reveals British Men Are Not Reaping Benefits of Local Health Services and Information

- Survey highlights men want to take charge of their health but need to be further supported in order to do so - Sanofi today announced findings from ...


11 Nov, 2016, 15:00 GMT Sanofi Presented Full Results of a PK/PD Study Comparing Toujeo® to Insulin Degludec in People With Type 1 Diabetes

- Toujeo® provides a flatter profile than insulin degludec with less within-day fluctuations - Sanofi presented today the full results of a...


28 Oct, 2016, 08:42 BST Sanofi CFO Interview - Q3 2016 Results (Video)

Sanofi, a global and diversified healthcare leader, reports results for the third quarter of 2016. Jérôme Contamine, Chief Financial Officer of...


15 Sep, 2016, 12:55 BST Toujeo® Demonstrates a More Stable Profile and Lower Within-day Variability Compared to Insulin Degludec

Further comparative data expected from ongoing head-to-head clinical trial Sanofi announced today the key results of a new pharmacokinetic /...


13 Sep, 2016, 11:33 BST Sanofi's Toujeo® Demonstrated a Consistently Lower Rate of Hypoglycemia Compared to Lantus® at All Levels of HbA1c control

- Benefits on adherence and HbA1c to be validated in a real-world setting - Sanofi announced today that adults with type 2 diabetes treated with...


29 Jul, 2016, 06:46 BST VIDEO: Sanofi - Q2 2016 Results Interview with CEO Olivier Brandicourt

Sanofi, a global and diversified healthcare leader, reports results for the second quarter of 2016. CEO Olivier Brandicourt comments on the results....


29 Apr, 2016, 10:11 BST Sanofi Q1 2016 Results

Sanofi, a global and diversified healthcare leader, reports results for the first quarter of 2016. Jérôme Contamine, Chief Financial Officer of...


04 Aug, 2015, 09:00 BST Sanofi's Insulin Toujeo® now Available for the Treatment of Adults with Diabetes in the UK

- New once-daily basal insulin demonstrated similar glycaemic control with a lower incidence of confirmed hypoglycaemia when compared to Lantus® in...


06 Jun, 2015, 15:01 BST Sanofi's Lyxumia® (lixisenatide) Statistically Superior to Rapid Acting Insulin for Body Weight Change with Similar Blood Sugar Control when Both are Added to Basal Insulin

Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia® (lixisenatide) met all co-primary endpoints in a clinical trial (GetGoal Duo-2)...


04 Jun, 2015, 06:00 BST Sanofi Announces Study Program Evaluating Toujeo® in a Real-Life Setting

- Study program to investigate patient experience and clinical effectiveness in people with type 2 diabetes - Sanofi (EURONEXT: SAN and NYSE: SNY)...


28 May, 2015, 15:22 BST Sanofi Announces Men With Advanced Prostate Cancer in England Will Continue to Have Access to Cabazitaxel (Jevtana®)

− Sanofi works with NHS England on interim agreement until NICE re-appraisal − Sanofi announced today that it has reached agreement with NHS England...


13 Mar, 2015, 14:15 GMT Patients With Advanced Prostate or Colorectal Cancer Face an Uncertainty in Their Future Treatment After NHS England Decision

Cabazitaxel (Jevtana®) and aflibercept (Zaltrap®▼), have been cut from the Cancer Drugs Fund (CDF) by NHS England, denying some cancer patients with...


10 Mar, 2015, 00:01 GMT Survey Shows That Oncologists Believe Cutting Drugs from Cancer Drugs Fund Won't Save NHS Money and Will Worsen Patient Outcomes[1]

In light of NHS England's plan to remove 25 uses of cancer medicines from the Cancer Drugs Fund (CDF) on 12 March[2], a new survey has revealed...